Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05251844 · ClinicalTrials.gov registry record · NA
The Effectiveness of Email Alerting on Reducing Employees' Unauthorized Access to Protected Health Information
A NA study of Unauthorized Data Access, sponsored by Protenus.
- Completed
- Registry status
- NA
- Development phase
- 444
- Enrollment target
- 1
- Study location
NCT05251844: Completed NA study of Unauthorized Data Access, sponsored by Protenus.
NCT05251844 is a NA study of Unauthorized Data Access that has completed, run by Protenus. The registered enrollment target is 444 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (68% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05251844, a NA study of Unauthorized Data Access, has completed, sponsored by Protenus.
- COMPLETED
- Registry status
- NA
- Development phase
- 444 participants
- Enrollment target
- 1
- Study location
Study Summary
To assess the effectiveness of email warnings on reducing repeated unauthorized access to Protected Health Information (PHI), a randomized trial was conducted in a large academic medical center to understand the effectiveness of email warning on reducing repeated unauthorized access to PHI.
Primary Outcome
The investigators monitored and collected all the subsequent unauthorized access violations for both the experiment and the control group
Conditions Studied
Interventions
- OTHER receiving an email
Study Locations (1)
Maryland
- Protenus, Inc. - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 444 participants |
| Start Date | 2018-01-01 |
| Est. Completion | 2021-09-30 |
| Phase | NA |
What the finished NCT05251844 record still lists
NCT05251844 is an interventional study that assigns participants to a tested intervention. The registered 444 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (68% lower).
The record links to 1 condition, with Unauthorized Data Access appearing as the primary indexed condition, and to 1 intervention - of which receiving an email is the first listed.
NCT05251844 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT05251844 about?
NCT05251844 is a clinical study titled "The Effectiveness of Email Alerting on Reducing Employees' Unauthorized Access to Protected Health Information". To assess the effectiveness of email warnings on reducing repeated unauthorized access to Protected Health Information (PHI), a randomized trial was conducted in a large academic medical center to understand the effectiveness of email warning on reducing repeated unauthorized access to PHI.
What is the current status of trial NCT05251844?
This trial is currently completed. It is a NA study. The enrollment target is 444 participants. The study started on 2018-01-01. Estimated completion is 2021-09-30.
What conditions does trial NCT05251844 study?
This clinical trial studies the following conditions: Unauthorized Data Access.
What interventions are being tested in trial NCT05251844?
The interventions under investigation include: receiving an email (OTHER).
Who is sponsoring clinical trial NCT05251844?
This trial is sponsored by Protenus, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05251844 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05251844's enrollment target sits among peer trials
444 233rd of 2000 higher than 1,768 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06348394 · 444 participants · NA
Intracardiac Versus Transesophageal Echocardiographic Guidance for Left Atrial Appendage Occlusion
- NCT06700343 · 444 participants · Phase 3
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)
- NCT01280994 · 445 participants · Phase 2
Hyperpolarized 129Xe MRI for Imaging Pulmonary Function
- NCT03504800 · 445 participants
OCT in Diagnosis of Irregular Corneas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI